Molecular determinants of trastuzumab efficacy: What is their clinical relevance?

Cancer Treatment Reviews

Volumn 39, Issue 8, 2013, Pages 925-934

  De, Pradip ^a   Hasmann, Max ^b   Leyland Jones, Brian ^a  

^a SANFORD RESEARCH   (United States)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Biomarker; Breast cancer; HER2; Trastuzumab

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 2; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BREAST CANCER; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NONHUMAN; PATIENT SELECTION; REVIEW; TUMOR GROWTH;

BIOMARKER; BREAST CANCER; HER2; TRASTUZUMAB;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84883558058     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.02.006     Document Type: Review

References (86)

1. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
2. Smith I., Procter M., Gelber R.D., et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
3. Slamon D., Eiermann W., Robert N., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365:1273-1283.
4. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
5. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
6. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
7. Franklin M.C., Carey K.D., Vajdos F.F., et al. Insights into ErbB signaling from the structure of the ErbB2-Pertuzumab complex. Cancer Cell 2004, 5:317-328.
8. Junttila T.T., Akita R.W., Parsons K., et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440.
9. Baselga J., Cortes J., Kim SB., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119.
10. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
11. NCCN Clinical Practice Guidelines in Oncology Breast Cancer 2012, V. 2.
12. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
13. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-2648.
14. Spector N.L., Blackwell K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27:5838-5847.
15. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16:1647-1655.
16. Lee-Hoeflich S.T., Crocker L., Yao E., et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008, 68:5878-5887.
17. Arribas J., Baselga J., Pedersen K., Parra-Palau J.L. p95HER2 and breast cancer. Cancer Res 2011, 71:1515-1519.
18. Molina M.A., Codony-Servat J., Albanell J., et al. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001, 61:4744-4749.
19. Carson W.E., Parihar R., Lindemann M.J., et al. Interleukin-2 enhances the natural killer cell response to herceptin-coated HER2/neu-positive breast cancer cells. Eur J Immunol 2001, 31:3016-3025.
20. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000, 6:443-446.
21. Arnould L., Gelly M., Penault-Llorca F., et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer 2006, 94:259-267.
22. Gennari R., Menard S., Fagnoni F., et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004, 10:5650-5655.
23. Varchetta S., Gibelli N., Oliviero B., et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing HER2. Cancer Res 2007, 67:11991-11999.
24. Beano A., Signorino E., Evangelista A., et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 2008, 6:25.
25. Scaltriti M., Rojo F., Ocana A., et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007, 99:628-638.
26. Sperinde J., Jin X., Banerjee J., et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res 2010, 16:4226-4235.
27. Villasboas J.C., Hurley J., Weiner L.M., Paquet A., Fernandez C.G., Lavina M.C., Sperinde J. Correlation of quantitative p95HER2 and HER2 protein expression with pathologic complete response (pCR) in HER2-positive breast cancer patients (pts) treated with neoadjuvant (neo) trastuzumab-containing therapy. J Clin Oncol 2012, 30(SUPPL.). [Abstr 608].
28. Guarneri V., Frassoldati A., Bottini A., Generali D.G., Cagossi K., Artioli F., Bisagni G. Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). J Clin Oncol 2011, 29(SUPPL.). [Abstr 507].
29. Gianni L., Bianchini G., Kiermaier A., Bianchi G., Im Y.H., Pienkowski T., Roman L. Neoadjuvant pertuzumab (P) and trastuzumab (H): biomarker analyses of a 4-arm randomized phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC). Cancer Res 2011, 71(SUPPL. 3). [Abstr S5-1].
30. Loibl S., Bruey G., Von Minckwitz G., Huober J., Press M.F., Darb-Esfahani F., et al. Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer. J Clin Oncol 2011, 29(SUPPL.). [Abstr 530].
31. Leyland-Jones B., Smith B.R. Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. Lancet Oncol 2011, 12:286-295.
32. Bose R., Kavuri S.M., Searleman A.C., et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013, 3:224-237.
33. Prempree T., Wongpaksa C. Mutations of HER2 gene in HER2-positive metastatic breast cancer. J Clin Oncol 2006, 18(SUPPL.). [Abstr 13118].
34. Perez-Tenorio G., Alkhori L., Olsson B., et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007, 13:3577-3584.
35. Nagata Y., Lan K.H., Zhou X., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
36. Berns K., Horlings H.M., Hennessy B.T., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
37. Fujita T., Doihara H., Kawasaki K., et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of Erbb2-overexpressing breast cancer. Br J Cancer 2006, 94:247-252.
38. Gallardo A., Lerma E., Escuin D., et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 2012, 106:1367-1373.
39. Gori S., Sidoni A., Colozza M., et al. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol 2009, 20:648-654.
40. Chandarlapaty S., Sakr R.A., Giri D., et al. Frequent mutational activation of the PI3K-Akt pathway in trastuzumab-resistant breast cancer. Clin Cancer Res 2012, 18:6784-6791.
41. Esteva F.J., Guo H., Zhang S., et al. PTEN, PIK3CA, p-Akt, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010, 177:1647-1656.
42. Razis E., Bobos M., Kotoula V., et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 2011, 128:447-456.
43. Barbareschi M., Cuorvo L.V., Girlando S., et al. PI3KCA mutations and/or PTEN loss in HER2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-HER2 therapy. Virchows Arch 2012, 461:129-139.
44. Fabi A., Metro G., Di B.A., et al. Clinical significance of PTEN and p-AKT co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Oncology 2010, 78:141-149.
45. Baselga J., Cortes J., Im S.A., Clark E., Kiermaier A., Ross G., Swain S.M. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Cancer Res 2012, 72(SUPPL. 3). [Abstr S5-1].
46. Loi S., Haibe-Kains B., Majjaj S., et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 2010, 107:10208-10213.
47. Faratian D., Goltsov A., Lebedeva G., et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN In resistance to trastuzumab. Cancer Res 2009, 69:6713-6720.
48. Faratian D., Sims A.H., Mullen P., et al. Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy. Plos One 2011, 6:E23772.
49. Jensen J.D., Knoop A., Laenkholm A.V., et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 2012, 23:2034-2042.
50. Perez E.A., Dueck A.C., Reinholz M.M., Chen B., Geiger X., Jenkins R.B., Lingle Wl. Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831. J Clin Oncol 2011, 29(SUPPL.). [Abstr 10504].
51. Yonemori K., Tsuta K., Shimizu C., et al. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med Oncol 2009, 26:344-349.
52. Dave B., Migliaccio I., Gutierrez M.C., et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 2011, 29:166-173.
53. Hamel S., Bouchard A., Ferrario C., et al. Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers. Breast Cancer Res Treat 2010, 120:47-57.
54. Zhang S., Huang W.C., Li P., et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011, 17:461-469.
55. Scaltriti M., Eichhorn P.J., Cortes J., et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci USA 2011, 108:3761-3766.
56. Yakes F.M., Chinratanalab W., Ritter C.A., et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002, 62:4132-4141.
57. Lee-Hoeflich S.T., Pham T.Q., Dowbenko D. PPM1H is a p27 phosphatase implicated in trastuzumab resistance. Cancer Discov 2011, 1:326-337.
58. Diermeier S., Horvath G., Knuechel-Clarke R., et al. Epidermal growth factor receptor coexpression modulates susceptibility to herceptin in HER2/Neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005, 304:604-619.
59. Mith B.L., Chin D., Maltzman W., et al. The efficacy of herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer 2004, 91:1190-1194.
60. Hudelist G., Kostler W.J., Czerwenka K., et al. Her-2/Neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Int J Cancer 2006, 118:1126-1134.
61. Robinson A.G., Turbin D., Thomson T., et al. Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease. Clin Breast Cancer 2006, 7:254-261.
62. Gori S., Foglietta J., Mameli M.G., et al. HER-3 status by immunohistochemistry in HER-2-positive metastatic breast cancer patients treated with trastuzumab: correlation with clinical outcome. Tumori 2012, 98:39-44.
63. Sassen A., Diermeier-Daucher S., Sieben M., et al. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer. Breast Cancer Res 2009, 11:R50.
64. Lu Y., Zi X., Zhao Y., Mascarenhas D., Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001, 93:1852-1857.
65. Shimizu C., Hasegawa T., Ando M., Fujiwara Y., Tani Y. Relation between insulin-like growth factor-1 receptor (IGF-1R) expression and the efficacy of trastuzumab (T) monotherapy for hormone-resistant HER2-postitive metastatic breast cancer (MBC). J Clin Oncol 2004, 22(SUPPL.). [Abstr 9578].
66. Kostler W.J., Hudelist G., Rabitsch W., et al. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/Neu overexpressing metastatic breast cancer. J Cancer Res Clin Oncol 2006, 132:9-18.
67. Reinholz M.M., Dueck A.C., Chen B., Geiger X., Mccullough A.E., Jenkins R.B., Lingle W.L. Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial. J Clin Oncol 2011, 29(SUPPL.). [Abstr 10503].
68. Harris L.N., You F., Schnitt S.J., et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007, 13:1198-1207.
69. Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
70. Bianchini G., Prat A., Pickl M., Belousov A., Koehler A., Semiglazov V., Eiermann W. Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: gene expression analysis. J Clin Oncol 2011, 29(SUPPL.). [Abstr 529].
71. Lesniak D., Xu Y., Deschenes J., et al. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res 2009, 69:8620-8628.
72. Valabrega G., Montemurro F., Sarotto I., et al. TGFalpha expression impairs trastuzumab-induced HER2 downregulation. Oncogene 2005, 24:3002-3010.
73. De Alava E., Ocana A., Abad M., et al. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol 2007, 25:2656-2663.
74. Buzdar A.U. Role of biologic therapy and chemotherapy in hormone receptor-and HER2-positive breast cancer. Ann Oncol 2009, 20:993-999.
75. Gianni L., Pienkowski T., Im Y.H., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:25-32.
76. Montemurro F., Rossi V., Cossu R.M., et al. Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer 2012, 118:17-26.
77. Brufsky A., Lembersky B., Schiffman K., Lieberman G., Paton V.E. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer 2005, 6:247-252.
78. Musolino A., Naldi N., Bortesi B., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/Neu-positive metastatic breast cancer. J Clin Oncol 2008, 26:1789-1796.
79. Tamura K., Shimizu C., Hojo T., et al. FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 2011, 22:1302-1307.
80. Hurvitz S.A., Betting D.J., Stern H.M., et al. Analysis of Fcgamma receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res 2012, 18:3478-3486.
81. De P.K., Sun Y., Wu H., Rommel C., Yi L., Dey N., Leyland-Jones B. Pre-clinical potency of INK128, a highly potent TORC1/2 kinase inhibitor in the HER2 amplified breast cancer model. Cancer Res 2012, 72(SUPPL.). [Abstr 2240].
82. Liang K., Esteva F.J., Albarracin C., et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated SRC activation and PTEN inactivation. Cancer Cell 2010, 18:423-435.
83. Osipo C., Patel P., Rizzo P., et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 2008, 27:5019-5032.
84. Cortes J., Fumoleau P., Bianchi G.V., et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012, 30:1594-1600.
85. Budzynski W., Radzikowski C. Cytotoxic cells in immunodeficient athymic mice. Immunopharmacol Immunotoxicol 1994, 16:319-346.
86. Nimmerjahn F., Bruhns P., Horiuchi K., Ravetch J.V. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005, 23:41-51.